Plain-English translation of NCT06794489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Charcot-Marie-Tooth disease (CMT) is a genetic nerve disorder that can gradually affect muscle strength and sensation. Right now, doctors mainly rely on physical exams and nerve tests to measure how the disease is progressing — but these tests can be slow and don't always catch subtle changes. This study is looking for biological markers (measurable signs in your body) that could provide a faster, more reliable way to track disease progression and test new treatments.
Current methods for measuring disease progression in Charcot-Marie-Tooth disease are limited and slow to show changes. Researchers have found promising early evidence that changes in skin cells and muscle imaging might reflect disease severity better than traditional exams, but this hasn't been tested in larger groups of patients yet. This trial aims to confirm whether these new markers could become practical tools for monitoring the disease.
You likely qualify if…
You likely don't qualify if…
As a participant, you would undergo skin biopsies and possibly muscle imaging scans (MRI) to look for biological changes related to your disease. You would also complete standard physical and neurological exams. The study is longitudinal, meaning you may be followed over time with repeat visits to track changes. The exact number and spacing of visits would be determined by the research team.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Germany